Key facts
- This page summarizes Matthew T. Wiley's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Oct 2024, 21:55.
Matthew T. Wiley - 17 Sep 2024 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- BTAI
- Reported as of
- 17 Sep 2024
- Net transaction value
- -$3,450
- SEC form
- 4
- Accepted by SEC
- 03 Oct 2024, 21:55:39 UTC
- Prior SEC filing
- 17 Sep 2024
- Next SEC filing
- 18 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Steinhart, Attorney-in-Fact for Matthew Wiley
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew T. Wiley filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 03 Oct 2024.
Change
- Previous filing in this sequence was filed on 17 Sep 2024.
- Current net transaction value: -$3,450.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTAI
transaction
Common Stock
Award
- Transaction value
- Shares
- +21,250
- Change %
- +527%
- Price
- Shares after
- 25,283
- Date
- 17 Sep 2024
- Ownership
- Direct
- Footnotes
- F1
BTAI
transaction
Common Stock
Sale
- Transaction value
- $3,450
- Shares
- -6,272
- Change %
- -25%
- Price
- $0.5500
- Shares after
- 19,011
- Date
- 03 Oct 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.